ELTP — Elite Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $544.92m
- $542.49m
- $84.04m
- 93
- 20
- 45
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.18 | ||
| Price to Tang. Book | 11.38 | ||
| Price to Free Cashflow | 110.52 | ||
| Price to Sales | 6.48 | ||
| EV to EBITDA | 24.96 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.18% | ||
| Return on Equity | -7.77% | ||
| Operating Margin | 23.32% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 25.38 | 32.26 | 34.16 | 56.63 | 84.04 | n/a | n/a | 36.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +88.84 | -67.16 | +541.18 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
Directors
- Nasrat Hakim CHM (60)
- Marc Bregman CFO (50)
- Douglas Plassche EVP (58)
- Jason LePree VPR
- Carter Ward TRS (57)
- Davis Caskey IND (73)
- Barry Dash IND (90)
- Jeffrey Whitnell IND (65)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- January 5th, 2012
- Public Since
- February 20th, 2014
- No. of Shareholders
- 105
- No. of Employees
- 68
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,068,463,108
- Address
- 165 Ludlow Ave, NORTHVALE, 07647-2305
- Web
- https://www.elitepharma.com/
- Phone
- +1 2017502646
- Contact
- Dianne Will
- Auditors
- Forvis Mazars LLP
Upcoming Events for ELTP
Q2 2026 Elite Pharmaceuticals Inc Earnings Release
Similar to ELTP
Acusphere
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Aleafia Health
Pink Sheets on Nasdaq
FAQ
What is the Elite Pharmaceuticals share price?
As of Today at 02:25 UTC, shares in Elite Pharmaceuticals are trading at $0.51. This share price information is delayed by 15 minutes.
How has the Elite Pharmaceuticals share price performed this year?
Shares in Elite Pharmaceuticals last closed at $0.51 and the price had moved by +174.19% over the past 365 days. In terms of relative price strength the Elite Pharmaceuticals share price has outperformed the S&P500 Index by +137.18% over the past year.
What are the analyst and broker recommendations for Elite Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Elite Pharmaceuticals dividend yield?
Elite Pharmaceuticals does not currently pay a dividend.
Does Elite Pharmaceuticals pay a dividend?
Elite Pharmaceuticals does not currently pay a dividend.
When does Elite Pharmaceuticals next pay dividends?
Elite Pharmaceuticals does not currently pay a dividend.
How do I buy Elite Pharmaceuticals shares?
To buy shares in Elite Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Elite Pharmaceuticals?
As of the previous close price of $0.51, shares in Elite Pharmaceuticals had a market capitalisation of $544.92m.
Where are Elite Pharmaceuticals shares listed?
Here are the trading details for Elite Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ELTP
What kind of share is Elite Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Elite Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Elite Pharmaceuticals share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Elite Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elite Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -6.14%.
As of the last closing price of $0.51, shares in Elite Pharmaceuticals were trading -2.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Elite Pharmaceuticals PE Ratio?
The Elite Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Elite Pharmaceuticals?
Elite Pharmaceuticals' management team is headed by:
- Nasrat Hakim - CHM
- Marc Bregman - CFO
- Douglas Plassche - EVP
- Jason LePree - VPR
- Carter Ward - TRS
- Davis Caskey - IND
- Barry Dash - IND
- Jeffrey Whitnell - IND